Global pharmaceutical company Lupin has announced the divestiture of its U.S. Commercial Women’s Health Specialty Business to Evofem Biosciences, a biopharmaceutical company dedicated to women’s health. This strategic move includes the transfer of SOLOSEC (secnidazole) 2g oral granules, an FDA-approved antimicrobial agent for treating bacterial vaginosis (BV) and trichomoniasis.
The agreement provides Lupin with the opportunity to receive up to USD 84 million based on future contingent milestones. Dr. Fabrice Egros, President of Global Corporate Development at Lupin, stated: “We are very pleased to divest our U.S. Commercial Women’s Health Specialty business, including SOLOSEC, to Evofem. This divestment aligns our U.S. specialty business with our strategic plan to focus on therapeutic areas where we have synergy, such as respiratory and neurological diseases.”
Evofem’s CEO, Saundra Pelletier, commented: “The acquisition of this commercial business aligns with and advances our mission to improve access to innovative and differentiated options that impact women’s daily lives. SOLOSEC is a commercially attractive, single-dose oral antibiotic that addresses two pervasive sexual health infections. We can now fully leverage our commercial infrastructure, maximize our strong physician relationships, and re-launch an asset with tremendous growth potential.”
